Literature DB >> 6745307

Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species.

H Boxenbaum, J B Fertig.   

Abstract

The intrinsic clearance of unbound drug (CLuint) for antipyrine in 15 mammalian species was characterized by an equation of the form, CLuint = theta 1 (body weight) theta 2 (brain weight) theta 3, where thetas are constants. Maximum lifespan potential in mammals can also be characterized by an equation of this form. It is suggested that the set of genetic mechanisms regulating longevity and other constitutional characteristics in species is also linked to rates of drug metabolism. The ability to scale interspecies data in pharmacokinetics is taken as an expression of this design principle.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6745307     DOI: 10.1007/BF03189622

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  9 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Influence of route of administration on drug availability.

Authors:  M Rowland
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

Review 3.  Allometry and size in ontogeny and phylogeny.

Authors:  S J Gould
Journal:  Biol Rev Camb Philos Soc       Date:  1966-11

4.  Interspecies pharmacokinetic scaling and the Dedrick plots.

Authors:  H Boxenbaum; R Ronfeld
Journal:  Am J Physiol       Date:  1983-12

Review 5.  Evolutionary biology, animal behavior, fourth-dimensional space, and the raison d'etre of drug metabolism and pharmacokinetics.

Authors:  H Boxenbaum
Journal:  Drug Metab Rev       Date:  1983       Impact factor: 4.518

6.  Models' limits suggest reflexivity in nature.

Authors:  H Fethe
Journal:  Am J Physiol       Date:  1982-03

7.  Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics.

Authors:  H Boxenbaum
Journal:  J Pharmacokinet Biopharm       Date:  1982-04

8.  Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.

Authors:  K S Pang; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

9.  Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin.

Authors:  H Boxenbaum
Journal:  J Pharmacokinet Biopharm       Date:  1980-04
  9 in total
  15 in total

Review 1.  Prediction of hepatic metabolic clearance: comparison and assessment of prediction models.

Authors:  J Zuegge; G Schneider; P Coassolo; T Lavé
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations.

Authors:  T Lavé; P Coassolo; B Reigner
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 3.  Applications of human pharmacokinetic prediction in first-in-human dose estimation.

Authors:  Peng Zou; Yanke Yu; Nan Zheng; Yongsheng Yang; Hayley J Paholak; Lawrence X Yu; Duxin Sun
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

4.  Scaling toxicity data across species.

Authors:  W R Chappell
Journal:  Environ Geochem Health       Date:  1992-10       Impact factor: 4.609

5.  Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.

Authors:  Jie Zhao; Yanguang Cao; William J Jusko
Journal:  Pharm Res       Date:  2015-05-05       Impact factor: 4.200

Review 6.  The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.

Authors:  I Mahmood; J D Balian
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

Review 7.  The use of toxicokinetics for the safety assessment of drugs acting in the brain.

Authors:  D B Campbell
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

8.  Interspecies scaling of bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling.

Authors:  T Lave; P Coassolo; G Ubeaud; R Brandt; C Schmitt; S Dupin; D Jaeck; R C Chou
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

9.  Predicting oral clearance in humans: how close can we get with allometry?

Authors:  Vikash K Sinha; Stefan S De Buck; Luca A Fenu; Johan W Smit; Marjoleen Nijsen; Ron A H J Gilissen; Achiel Van Peer; Karel Lavrijsen; Claire E Mackie
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  Interspecies scaling of tebufelone pharmacokinetic data and application to preclinical toxicology.

Authors:  C A Cruze; G R Kelm; M P Meredith
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.